Levodopa-induced dyskinesias in Parkinson's disease: Is sensitization reversible?

Annals of Neurology

Volumn 47, Issue 5, 2000, Pages 655-658

  Bejjani, Boulos Paul ^a,b   Arnulf, Isabelle ^a   Demeret, Sophie ^a   Damier, Philippe ^a   Bonnet, Anne Marie ^a   Houeto, Jean Luc ^a   Agid, Yves ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b U des Troubles du Mouvement   (Lebanon)

Author keywords

[No Author keywords available]

Indexed keywords

LEVODOPA;

ADULT; AGED; ARTICLE; BRAIN DEPTH STIMULATION; CLINICAL ARTICLE; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; DYSKINESIA; DYSTONIA; FEMALE; HUMAN; MALE; ON OFF PHENOMENON; PARKINSON DISEASE; PRIORITY JOURNAL; SENSITIZATION; SUBTHALAMIC NUCLEUS;

EID: 0034059617     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/1531-8249(200005)47:5<655::aid-ana16>3.0.co;2-%23     Document Type: Article

References (15)

1. Agid Y. Levodopa: is toxicity a myth? Neurology 1998;50:858-863
2. Agid Y, Bonnet AM, Ruberg M, Javoy-Agid F. Pathophysiology of L-dopa-induced abnormal involuntary movements. In: Casey D, Chase T, Christensen A, Gerlach J, eds. Dyskinesia. Berlin: Springer, 1985:145-149
3. Fahn S, Elton R. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne D, Goldstein M, eds. Recent developments in Parkinson's disease. 2nd ed. New Jersey: Mac-Millan Healthcare Informarion, 1987:153-163
4. Bejjani B, Damier P, Arnulf I, et al. Pallidal stimulation for Parkinson's disease: two targets? Neurology 1997;49:1564-1569
5. Koller WC, Weiner WJ, Perlik S, et al. Complications of chronic levodopa therapy: long-term efficacy of drug holiday. Neurology 1981;31:473-476
6. Feldman RG, Kaye JA, Lannon MC. Parkinson's disease: follow-up after "drug holiday." J Clin Pharmacol 1986;26:662-607
7. Mayeux R, Stern Y, Mulvey K, Cote L. Reappraisal of temporary levodopa withdrawal ("drug holiday") in Parkinson's disease. N Engl J Med 1985;313:724-728
8. Nutt JG, Carter JH, Lea ES, Woodward WR. Motor fluctuations during continuous levodopa infusions in patients with Parkinson's disease. Mov Disord 1997;12:285-292
9. Schuh LA, Bennett JP, Jr. Suppression of LIDs in advanced Parkinson's disease. I. Continuous intravenous levodopa shifts dose response for production of LIDs but not for relief of parkinsonism in patients with advanced Parkinson's disease. Neurology 1993;43:1545-1550
10. Stocchi F, Patsalos PN, Berardelli A, et al. Clinical implications of sustained dopaminergic stimulation. Clin Neuropharmacol 1994;17(suppl 2):S7-S13
11. Lee MS, Marsden CD. Movement disorders following lesions of the thalamus or subthalamic region. Mov Disord 1994;9: 493-507
12. Limousin P, Pollak P, Hoffmann D, et al. Abnormal involuntary movements induced by subthalamic nucleus stimulation in parkinsonian patients. Mov Disord 1996;11:231-235
13. Caraceni T, Scigliano G, Musicco M. The occurrence of motor fluctuations in parkinsonian patients treated long-term with levodopa: role of early treatment and disease progression. Neurology 1991;41:380-384
14. Juncos JL, Engber TM, Raisman R, et al. Continuous and intermittent levodopa differentially affects basal ganglia function. Ann Neurol 1989;25:473-478
15. Mouradian MM, Heuser IJ, Baronti F, Chase TN. Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease. Ann Neurol 1990;27:18-23